Dr. Vinod Pullarkat, M.D.
Hematology (Hematology (Internal Medicine) Physician)
1500 Duarte Rd
Duarte, CA 91010
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 182
Licensed in California since 1997, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
CA license A63417 (first issued 1997; current) -
Hematology & Oncology Physician
CA license A63417 (first issued 1997; current) -
Internal Medicine Physician
CA license A63417 (first issued 1997; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- City of Hope Medical Foundation (982 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 182
- Services billed
- 600
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 387 | 102 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 159 | 38 |
| New patient office or other outpatient visit, 60-74 minutes | 18 | 18 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jakafi (ruxolitinib phosphate) | 80 |
| Warfarin Sodium Other prescribers in Duarte, CA | 63 |
| Eliquis (apixaban) Other prescribers in Duarte, CA | 62 |
| Enoxaparin Sodium Other prescribers in Duarte, CA | 42 |
| Acyclovir Other prescribers in Duarte, CA | 35 |
| Xarelto (rivaroxaban) Other prescribers in Duarte, CA | 25 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Duarte, CA | 24 |
| Doptelet (avatrombopag maleate) | 17 |
| Iclusig (ponatinib hcl) | 16 |
| Venclexta (venetoclax) | 15 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 86 payments worth $91,701 in total to this clinician.
| Alexion Pharmaceuticals, Inc. | $42,178 |
|---|---|
| Novartis Pharmaceuticals Corporation | $35,987 |
| AbbVie Inc. | $8,012 |
| Jazz Pharmaceuticals Inc. | $3,111 |
| Genzyme Corporation | $1,662 |
| Syndax Pharmaceuticals, Inc. | $214 |
| Beone Medicines USA, Inc. | $180 |
| Sobi, Inc | $151 |
| Consulting Fee | $72,485 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $10,311 |
| Travel and Lodging | $6,061 |
| Food and Beverage | $2,736 |
| Education | $109 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Alexion Pharmaceuticals, Inc. Aug 18, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $15,600 |
| Novartis Pharmaceuticals Corporation Feb 25, 2025 | Consulting Fee | $12,325 |
| Alexion Pharmaceuticals, Inc. Mar 20, 2025 | Consulting Fee | $10,920 |
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Consulting Fee | $7,750 |
| Alexion Pharmaceuticals, Inc. Nov 13, 2025 | Consulting Fee | $3,900 |
| Alexion Pharmaceuticals, Inc. Jul 4, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $3,705 |
| Novartis Pharmaceuticals Corporation Dec 23, 2025 | Consulting Fee Fabhalta · Immunology | $3,500 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $3,000 |
| AbbVie Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $3,000 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Consulting Fee Fabhalta · Immunology | $2,750 |
All 45 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 23, 2025 | Consulting Fee Fabhalta · Immunology | $3,500 |
| AbbVie Inc. Dec 18, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $300 |
| AbbVie Inc. Dec 11, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $3,000 |
| Alexion Pharmaceuticals, Inc. Nov 13, 2025 | Consulting Fee | $3,900 |
| Jazz Pharmaceuticals Inc. Oct 22, 2025 | Compensation for services other than consulting (speaking, faculty) DEFITELIO · HEMATOLOGY/ONCOLOGY | $2,649 |
| Alexion Pharmaceuticals, Inc. Sep 15, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA Company’s descriptionConsulting Expenses | $144 |
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Consulting Fee | $7,750 |
| Novartis Pharmaceuticals Corporation Aug 27, 2025 | Travel and Lodging travel to East Hanover, NJ | $115 |
| Alexion Pharmaceuticals, Inc. Aug 18, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $15,600 |
| Novartis Pharmaceuticals Corporation Aug 11, 2025 | Travel and Lodging travel to East Hanover, NJ | $235 |
| Novartis Pharmaceuticals Corporation Aug 11, 2025 | Travel and Lodging travel to East Hanover, NJ · in-kind | $228 |
| Novartis Pharmaceuticals Corporation Aug 10, 2025 | Travel and Lodging travel to East Hanover, NJ · in-kind | $800 |
| Alexion Pharmaceuticals, Inc. Jul 30, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA · in-kind Company’s descriptionConsulting Expenses | $757 |
| Alexion Pharmaceuticals, Inc. Jul 30, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Boston, MA · in-kind Company’s descriptionConsulting Expenses | $302 |
| Alexion Pharmaceuticals, Inc. Jul 24, 2025 | Consulting Fee | $2,730 |
| Alexion Pharmaceuticals, Inc. Jul 24, 2025 | Consulting Fee | $2,730 |
| Novartis Pharmaceuticals Corporation Jul 21, 2025 | Consulting Fee | $1,925 |
| Novartis Pharmaceuticals Corporation Jul 17, 2025 | Travel and Lodging travel to Jersey City, NJ · in-kind | $577 |
| AbbVie Inc. Jul 17, 2025 | Education EPKINLY · ONCOLOGY · in-kind | $9.65 |
| Alexion Pharmaceuticals, Inc. Jul 4, 2025 | Consulting Fee ULTOMIRIS · Rare Disease | $3,705 |
| AbbVie Inc. Jul 4, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $600 |
| Novartis Pharmaceuticals Corporation Jun 13, 2025 | Consulting Fee Fabhalta · Immunology | $700 |
| AbbVie Inc. Jun 9, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $600 |
| Seagen Inc. Jun 5, 2025 | Education in-kind | $99.00 |
| Novartis Pharmaceuticals Corporation May 26, 2025 | Consulting Fee | $2,450 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $3,000 |
| Alexion Pharmaceuticals, Inc. Mar 20, 2025 | Consulting Fee | $10,920 |
| Genzyme Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) WAYRILZ · Immunology | $1,662 |
| Alexion Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s descriptionConsulting Expenses | $87.04 |
| Alexion Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging travel to Los Angeles, CA Company’s descriptionConsulting Expenses | $54.99 |
| Alexion Pharmaceuticals, Inc. Feb 28, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s descriptionConsulting Expenses | $43.52 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Dallas, TX · in-kind Company’s descriptionConsulting Expenses | $452 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Fort Worth, TX · in-kind Company’s descriptionConsulting Expenses | $366 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Fort Worth, TX Company’s descriptionConsulting Expenses | $83.22 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Travel and Lodging travel to Los Angeles, CA Company’s descriptionConsulting Expenses | $43.05 |
| Novartis Pharmaceuticals Corporation Feb 25, 2025 | Consulting Fee | $12,325 |
| Novartis Pharmaceuticals Corporation Feb 25, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $290 |
| Novartis Pharmaceuticals Corporation Feb 25, 2025 | Travel and Lodging travel to JERSEY CITY, NJ | $280 |
| Novartis Pharmaceuticals Corporation Feb 25, 2025 | Travel and Lodging travel to JERSEY CITY, NJ · in-kind | $86.66 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Consulting Fee Fabhalta · Immunology | $2,750 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Travel and Lodging Fabhalta · Immunology · travel to LAS VEGAS, NV · in-kind | $248 |
| Novartis Pharmaceuticals Corporation Jan 14, 2025 | Travel and Lodging Fabhalta · Immunology · travel to LAS VEGAS, NV · in-kind | $42.00 |
| Novartis Pharmaceuticals Corporation Jan 13, 2025 | Travel and Lodging Fabhalta · Immunology · travel to Las Vegas, NV · in-kind | $391 |
| Novartis Pharmaceuticals Corporation Jan 13, 2025 | Travel and Lodging Fabhalta · Immunology · travel to Las Vegas, NV · in-kind | $227 |
| Novartis Pharmaceuticals Corporation Jan 13, 2025 | Travel and Lodging Fabhalta · Immunology · travel to Las Vegas, NV · in-kind | $209 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 5 companies. The companies reported $967,607 in research payments for these studies, mostly to the institutions running them.
- An Open Label, Multicenter Roll-over Extension Program (REP) to Characterize the Long-term Safety and Tolerability of Iptacopan (LNP023) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Completed PN…
Novartis Pharmaceuticals Corporation - Calaspargase pegol in adults with all
Servier Bioinnovation - A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
AbbVie Inc. · Completed · NCT03222609 - A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia
Genzyme Corporation · Recruiting · NCT07086976 - Real-world treatment patterns and outcomes in patients with immune thrombocytopenic purpura treated with Avatrombopag in the United States
Sobi, Inc - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. · Terminated · NCT04161885 - A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
Novartis Pharmaceuticals Corporation - A Multicenter, Single Arm, Open-label Trial to Evaluate Efficacy and Safety of Oral, Twice Daily Iptacopan in Adult PNH Patients Who Have Hb10 g/dL in Response to Anti-C5 Antibody and Switch to Iptacopan
Novartis Pharmaceuticals Corporation - M19-063 - A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)
AbbVie Inc. - A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie Inc. · Active, not recruiting · NCT04041050
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.